Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $44.0 million.

  • Voyager Therapeutics' Operating Expenses rose 1444.97% to $44.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.5 million, marking a year-over-year increase of 1087.07%. This contributed to the annual value of $163.3 million for FY2024, which is 2757.47% up from last year.
  • Per Voyager Therapeutics' latest filing, its Operating Expenses stood at $44.0 million for Q3 2025, which was up 1444.97% from $41.8 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Operating Expenses peaked at $44.6 million during Q2 2024, and registered a low of $20.1 million during Q2 2022.
  • For the 5-year period, Voyager Therapeutics' Operating Expenses averaged around $32.7 million, with its median value being $32.1 million (2021).
  • As far as peak fluctuations go, Voyager Therapeutics' Operating Expenses plummeted by 3294.04% in 2022, and later skyrocketed by 5642.46% in 2023.
  • Voyager Therapeutics' Operating Expenses (Quarter) stood at $22.4 million in 2021, then increased by 2.87% to $23.0 million in 2022, then skyrocketed by 56.42% to $36.0 million in 2023, then increased by 23.83% to $44.6 million in 2024, then fell by 1.39% to $44.0 million in 2025.
  • Its last three reported values are $44.0 million in Q3 2025, $41.8 million for Q2 2025, and $41.2 million during Q1 2025.